Portal de Periódicos da CAPES

Cyclosporin a in the treatment of chronic plaque psoriasis: Six years experience

1993; Informa; Volume: 4; Issue: 1 Linguagem: Inglês

10.3109/09546639309088228

1471-1753

HM Lewis, AV Powle, Emma Thomas‐Jones, JJ Garioch, BS Baker, B. Hulme, Thomas J. Cook, Helgi Valdimarsson, L. Fry,

Autoimmune Bullous Skin Diseases

Cyclosporin A (CyA) was used to treat 84 patients with severe chronic plaque psoriasis for 1–72 (mean 18.5) months. CyA treatment was effective with a mean (± SEM) reduction in PASI score of 70 ± 8% (P 30% rise in serum creatinine. There was a strong positive correlation between increase in serum creatinine and duration of treatment (r = 0.49; P < 0.001). In 71 patients glomerular filtration rate (GFR) was measured before commencing CyA and fell 16% from 110 (±3) ml/min at baseline to 94 (± 3) ml/min after treatment (P < 0.001). The fall in GFR correlated strongly with the length of treatment (r = 0.41; P < 0.001). Renal biopsies were performed on eight patients receiving long-term continuous CyA. Two biopsies showed features consistent with moderate CyA nephrotoxicity and therapy was discontinued. CyA is effective in the treatment of chronic plaque psoriasis. However, monitoring of renal function is mandatory and significant long-term side-effects may limit its use. (J Dermatol Treat (1993) 4: 3–7)